BTK and B-cell chronic lymphocytic leukemia: The orally administered, bioavailable BTK inhibitor ibrutinib has been FDA-approved to treat patients with relapsed mantle cell lymphoma (MCL), Waldenstrom’s macroglobulinemia, and chronic lymphocytic leukemia (CLL), including those harboring 17p deletion [15,16].